A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs.
AHTR
FNHTR
TACO
TRALI
dog
leukoreduction
storage lesion
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
received:
29
11
2023
accepted:
01
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
Reported incidence of blood transfusion reactions (TR) varies greatly. To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs. Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022. Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021. The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]). Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.
Sections du résumé
BACKGROUND
BACKGROUND
Reported incidence of blood transfusion reactions (TR) varies greatly.
OBJECTIVE
OBJECTIVE
To prospectively evaluate the incidence of acute TRs in dogs receiving allogenic blood products, using consensus definitions, and to assess factors associated with TRs.
ANIMALS
METHODS
Dogs (n = 858) administered allogenic blood products (n = 1542) between March and November 2022.
METHODS
METHODS
Prospective, multicenter surveillance study occurring in referral hospitals in the United States, United Kingdom, and Australia recording TRs in dogs administered blood products as defined by the consensus guidelines published by The Association of Veterinary Hematology and Transfusion Medicine in 2021.
RESULTS
RESULTS
The incidence of acute TR was 8.9% (95% CI 7.0-11.1) for packed red blood cells (pRBCs) and 4.5% (95% CI 2.9-6.6) for plasma products. The most frequently reported TRs were febrile nonhemolytic TRs (FNHTR; 4%, 95% CI 2.8-5.5) when administering pRBCs and allergic TRs (3.2%, 95% CI 1.80-5.10) when administering plasma products. A higher dose of pRBC (adjusted odds ratio [aOR] 1.04 [95% CI 1.00-1.08]) was associated with a higher odds of TR. Administration of pRBCs stored for longer than 28 days was associated with higher odds of FNHTR (aOR 4.10 [95% CI 1.58-10.65]) and acute hemolytic TR (AHTR; OR 15.2 [95% CI 3.35-68.70]) when compared with pRBCs stored for 14 days or fewer. Leukoreduction of pRBC was not associated with lower odds of developing a TR (OR 1.47 [95% CI 0.89-2.42]).
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Clinicians should be mindful of the age and dose of pRBC prescribed to dogs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Références
Hendrickson JE, Roubinian NH, Chowdhury D, et al. Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion. 2016;56:2587‐2596.
Davidow EB, Blois SL, Goy‐Thollot I, et al. Association of Veterinary Hematology and Transfusion Medicine (AVHTM) transfusion reaction small animal consensus statement (TRACS). Part 1: definitions and clinical signs. J Vet Emerg Crit Care. 2021;31:141‐166.
Holowaychuk MK, Leader JL, Monteith G. Risk factors for transfusion‐associated complications and nonsurvival in dogs receiving packed red blood cell transfusions: 211 cases (2008–2011). J Am Vet Med Assoc. 2014;244:431‐437.
Kerl M, Hohenhaus A. Packed red blood cell transfusions in dogs: 131 cases (1989). J Am Vet Med Assoc. 1993;202:1495‐1499.
Callan MB, Oakley DA, Shofer FS, Giger U. Canine red blood cell transfusion practice. J Am Anim Hosp Assoc. 1996;32:303‐311.
Odunayo A, Nash KJ, Davidow EB, et al. Association of Veterinary Hematology and Transfusion Medicine (AVHTM) Transfusion Reaction Small Animal Consensus Statement (TRACS). Part 3: diagnosis and treatment. J Vet Emerg Crit Care. 2021;31:189‐203.
Davidow EB, Blois SL, Goy‐Thollot I, et al. Association of Veterinary Hematology and Transfusion Medicine (AVHTM) transfusion reaction small animal consensus statement (TRACS) part 2: prevention and monitoring. J Vet Emerg Crit Care. 2021;31:167‐188.
Bruce JA, Kriese‐Anderson L, Bruce AM, Pittman JR. Effect of premedication and other factors on the occurrence of acute transfusion reactions in dogs. J Vet Emerg Crit Care. 2015;25:620‐630.
Davidow EB, Montgomery H, Mensing M. The influence of leukoreduction on the acute transfusion‐related complication rate in 455 dogs receiving 730 packed RBCs: 2014–2017. J Vet Emerg Crit Care. 2022;32:479‐490.
Maglaras CH, Koenig A, Bedard DL, Brainard BM. Retrospective evaluation of the effect of red blood cell product age on occurrence of acute transfusion‐related complications in dogs: 210 cases (2010–2012). J Vet Emerg Crit Care. 2017;27:108‐120.
Hann L, Brown DC, King LG, Callen MB. Effect of duration of packed red blood cell storage on morbidity and mortality in dogs after transfusion: 3,095 cases (2001–2010). J Vet Intern Med. 2014;28:1830‐1837.
Elias Santo‐Domingo N, Lewis DH. Indications for use and complications associated with canine plasma products in 170 patients. J Vet Emerg Crit Care. 2021;31:263‐268.
Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol. 2013;160:434‐444.
Goggs R, Brainard BM, LeVine DN, et al. Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: a multicenter randomized clinical trial. J Vet Intern Med. 2020;34:2384‐2397.
Davidow EB, Brainard B, Martin LG, et al. Use of fresh platelet concentrate or lyophilized platelets in thrombocytopenic dogs with clinical signs of hemorrhage: a preliminary trial in 37 dogs. J Vet Emerg Crit Care. 2012;22:116‐125.
Saint‐Pierre LM, Farrell KS, Hopper K, Reagan KL. Retrospective evaluation of fresh platelet concentrate administration in dogs: patient characteristics, outcomes, and transfusion practices in 189 transfusion episodes (2008‐2019). J Vet Emerg Crit Care. 2023;33:360‐370.
Ng ZY, Stokes JE, Alvarez L, Bartges JW. Cryopreserved platelet concentrate transfusions in 43 dogs: a retrospective study (2007–2013). J Vet Emerg Crit Care. 2016;26:720‐728.
Radulescu SM, Skulberg R, McDonald C, Chan DL, Humm K. Randomized double‐blinded clinical trial on acute transfusion reactions in dogs receiving leukoreduced versus nonleukoreduced packed red blood cells. J Vet Intern Med. 2021;35:1325‐1332.
Goel R, Tobian AA, Shaz BH. Noninfectious transfusion‐associated adverse events and their mitigation strategies. Blood. 2019;133:1831‐1839.
Sazama K. Reports of 355 transfusion‐associated deaths: 1976 through 1985. Transfusion. 1990;30:583‐590.
Odunayo A, Garraway K, Rohrbach BW, Rainey A, Stokes J. Incidence of incompatible crossmatch results in dogs admitted to a veterinary teaching hospital with no history of prior red blood cell transfusion. J Am Vet Med Assoc. 2017;250:303‐308.
Thomovsky EJ, Bach J. Incidence of acute lung injury in dogs receiving transfusions. J Am Vet Med Assoc. 2014;244:170‐174.
Vlaar APJ, Toy P, Fung M, et al. A consensus redefinition of transfusion‐related acute lung injury. Transfusion. 2019;59:2465‐2476.
White SK, Schmidt RL, Walker BS, Metcalf RA. The epidemiology of transfusion‐related acute lung injury: a scoping review and analysis. Transfusion. 2023;63:104‐116.
Shah A, Brunskill SJ, Desborough MJ, Doree C, Trivella M, Stanworth SJ. Transfusion of red blood cells stored for shorter versus longer duration for all conditions. Cochrane Database Syst Rev. 2018;2018:CD010801.
Holowaychuk MK, Musulin SE. The effect of blood usage protocol on the age of packed red blood cell transfusions administered at 2 veterinary teaching hospitals. J Vet Emerg Crit Care. 2015;25:679‐683.
Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or Liberal red‐cell transfusion for cardiac surgery. N Eng J Med. 2017;377:2133‐2144.
Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Eng J Med. 2014;371:1381‐1391.
King KE, Shirey RS, Thoman SK, Bensen‐Kennedy D, Tanz WS, Ness PM. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion. 2004;44:25‐29.
Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion. 2004;44:16‐24.
Bosch Lozano L, Blois SL, Wood RD, et al. A pilot study evaluating the effects of prestorage leukoreduction on markers of inflammation in critically ill dogs receiving a blood transfusion. J Vet Emerg Crit Care. 2019;29:385‐390.
Simancas‐Racines D, Osorio D, Martí‐Carvajal AJ, Arevalo‐Rodriguez I, Cochrane Injuries Group. Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion. Cochrane Database Syst Rev. 2015;2015:CD009745.
Brunskill S, Thomas S, Whitmore E, et al. What is the maximum time that a unit of red blood cells can be safely left out of controlled temperature storage? Transfus Med Rev. 2012;26:209‐223.e203.
Ramirez‐Arcos S, Mastronardi C, Perkins H, et al. Evaluating the 4‐hour and 30‐minute rules: effects of room temperature exposure on red blood cell quality and bacterial growth. Transfusion. 2013;53:851‐859.